Dr. Goy on the Approval of Pembrolizumab in PMBCL

Andre Goy, MD
Published: Wednesday, Jun 13, 2018



Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).

The approval was based on findings from a cohort of the phase II KEYNOTE-170, trial evaluating the anti–PD-1 agent in 29 patients with PMBCL. The trial is an ongoing, non-randomized, international, 2-cohort, multicenter study investigating pembrolizumab every 3 weeks in patients who relapsed after, were refractory to, or were ineligible for autologous stem cell transplant and failed 2 or more prior lines of therapy, and in patients with relapsed or refractory Richter syndrome.
SELECTED
LANGUAGE


Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).

The approval was based on findings from a cohort of the phase II KEYNOTE-170, trial evaluating the anti–PD-1 agent in 29 patients with PMBCL. The trial is an ongoing, non-randomized, international, 2-cohort, multicenter study investigating pembrolizumab every 3 weeks in patients who relapsed after, were refractory to, or were ineligible for autologous stem cell transplant and failed 2 or more prior lines of therapy, and in patients with relapsed or refractory Richter syndrome.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x